Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Bonus Article The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Authored by Chris Markoch. Article Published: 1/18/2026. 
What You Need to Know - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. Investors often target companies with disruptive technologies, exposure to emerging trends, or compelling turnaround stories. Many of these companies will never survive or scale, but if one succeeds, potential returns can be substantial. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. That's not a guarantee of success, but it can help gauge investor interest and build conviction. Over the past 40 years, one Wall Street legend earned the title Market Wizard by cutting through noise when something feels off in the markets. With President Trump's moves in Venezuela, everyone is buzzing about oil. But almost no one is seeing past the headlines to the real opportunity. The few who recognize what's happening are calling it a bull market hidden in plain sight. This may be your final chance to get positioned before this generational opportunity in American energy becomes obvious to everyone. Click here for the full details while there's still time. Some people define a penny stock as any share trading for $5 or less. This screener uses the traditional definition—stocks trading below $1. These securities are highly volatile; conduct your own research and ensure any position fits your risk tolerance before investing. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral, tablet-based vaccines for infectious diseases, including influenza, norovirus, and COVID-19. Unlike traditional injectable vaccines, Vaxart's platform aims to simplify distribution and improve global accessibility. The bullish case for Vaxart rests on its innovative delivery approach. If the company secures FDA approval and successfully scales production, its oral vaccines could reduce logistical barriers to mass immunization campaigns and create opportunities for significant licensing partnerships. Positive trial results or a commercial collaboration could materially change sentiment and valuation from the stock's current low base. Clinical risk is the primary challenge. Vaxart has yet to bring a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. MarketBeat's analyst coverage shows only a single analyst following Vaxart, which may concern some investors. The company has roughly 18% institutional ownership and about 2% short interest, which could temper some downside volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software solutions enable the precise 3D mapping needed for self-driving systems and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bullish thesis for Microvision depends on continued progress toward vehicle automation and the potential for partnerships with major automotive manufacturers. If the company can demonstrate performance or cost advantages, it could secure supply agreements or licensing deals that improve revenue visibility. Microvision's technology may also find applications beyond vehicles—in robotics and smart cities—adding optionality to its growth story. Despite the promise, Microvision faces stiff competition from LiDAR competitors such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The path to profitability is uncertain, and recurring delays in LiDAR adoption continue to frustrate investors. MVIS is covered by three analysts and carries a consensus price target of $2.50, implying a roughly 169% upside from its Jan. 15 closing price. Like many speculative names, Microvision has relatively low institutional ownership (around 30%) and elevated short interest (around 21%), so investors should expect high volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company's patented Datavault platform helps organizations convert raw data into tradable, revenue-generating assets by combining AI, blockchain, and analytics tools. Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems may overlook. The bullish case for Datavault AI centers on its niche focus and scalability potential. As data becomes increasingly valuable, businesses—and potentially individuals—are seeking ways to safely monetize digital information. Datavault's technology could benefit from broader AI adoption and growing awareness of data sovereignty. Early-stage traction or strategic partnerships could catalyze investor confidence. That said, Datavault AI operates in a highly experimental space. Its business model is still evolving, and the path to meaningful revenue growth remains unproven. Institutional ownership is below 1%, and short interest exceeds 16% at the time of writing. Investors should view DVLT as a long-term, speculative position based on belief in data-as-an-asset innovation rather than near-term earnings potential.
| 
